Complera Articles
Gilead’s Quad regimen to be HIV market leader in 2020, with over $3 billion sales, says Decision Resources
31 October 2011
Gilead gains US approval for Complera, resolves manufacturing problem and buys Genentech facility
11 August 2011
Showing 1-4 of 4 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
